GOP Senators Press FDA On Puberty Blocker Risks After Matt Walsh Exposes Vanderbilt Transgender Clinic

GOP Senators Press FDA On Puberty Blocker Risks After Matt Walsh Exposes Vanderbilt Transgender Clinic


Two GOP senators are pressing the FDA to provide data on the effects of a puberty-inhibiting drug recently warned about by some medical experts.

GOP Sens. Marsha Blackburn of Tennessee and Cynthia Lummis of Wyoming wrote a letter to FDA Commissioner Robert Califf on Thursday about the side-effects of gonadotropin-releasing hormone (GnRH) agonists, which are used to treat minors with early-onset puberty, as well as stave off the normal pubescent development of minors who may be considering sex-reassignment surgery.

The FDA added a warning to the use of GnRH agonists in July over reported cases of pseudotumor cerebri, a condition that mimics the symptoms of a brain tumor but has no obvious source. GnRH agonists are found in drugs such as Lupron Depot-Ped, Fensolvi, Synarel, Supprelin LA,

Trending: Why Was There A Goat At The Queen’s Funeral?

Continue reading


 

Join the conversation!

Please share your thoughts about this article below. We value your opinions, and would love to see you add to the discussion!

Thanks for sharing!
Send this to a friend